Last updated: July 28, 2026
Kadian is an oral, extended-release morphine sulfate product for opioid use disorder and chronic pain. Patent and FDA exclusivity timelines determine generic and authorized generic risk, while REMS and payer controls shape demand. A forward-looking market projection depends primarily on sustained opioid-safety scrutiny, competitive substitution within extended-release opioids, and access dynamics under managed care.
Because “Kadian” is a branded product with multiple strength presentations and a mature history, an actionable forecast requires the current clinical-trial pipeline by indication, endpoint status, and the latest FDA/Orange Book exclusivity and patent estate. Those specific, up-to-date inputs are not present in the provided information, so a complete and accurate clinical update and market projection cannot be produced.
What is the latest clinical trials update for Kadian (morphine sulfate extended release)?
No current, indication-specific, publicly documented Kadian-sponsored or Kadian-specific interventional trial status was provided. Without trial identifiers (NCT numbers), enrollment status, sponsor, and readout dates, the clinical trials update cannot be stated precisely.
Which indications is Kadian being studied for in current trials?
Kadian is used in chronic pain and opioid dependence frameworks, but the current trial landscape by indication is not provided.
What endpoints would move Kadian forward commercially?
For an extended-release opioid, commercial relevance typically depends on:
- analgesic efficacy in chronic pain settings
- opioid withdrawal or stability endpoints in dependence settings
- safety endpoints under opioid risk monitoring
- pharmacokinetic comparability for reformulation or generic-bridge studies
No trial endpoints or outcomes are supplied.
What patents protect Kadian (morphine sulfate ER) and how much exclusivity remains?
No Orange Book patent list, listed patents-by-substance, or expiration dates were provided for Kadian. Without:
- Orange Book code (active ingredient, dosage form, route)
- patent numbers
- statutory basis (composition, method, use, formulation, or manufacturing)
- expiration dates and any pediatric exclusivity or forfeiture details
a defensible exclusivity and litigation/risk assessment cannot be completed.
How strong is the Kadian patent estate versus generic extended-release morphine?
Patent strength ranking requires enumerating claims scope across:
- composition of matter (if any)
- specific formulation/manufacturing for the extended-release profile
- method-of-use claims tied to approved labeling
- polymorph, excipient system, or bead technology (if applicable)
No patent data were provided.
When does Kadian lose exclusivity and what generic entry risks exist?
A generic or authorized generic entry forecast requires:
- the earliest patent expiration and any pediatric extensions
- whether any patents are in litigation
- whether any Paragraph IV ANDAs were filed for equivalent dosage forms
- whether 505(b)(2) alternatives exist
None of those facts were provided.
What generic entry scenarios should be modeled?
Typical scenarios include:
- Paragraph IV ANDA litigation leading to 180-day exclusivity for a first filer
- settlement-driven “launch-block” periods
- multiple launches by strength or by formulation line
- market share displacement through payer formularies
No Kadian-specific scenario facts are available in the provided inputs.
What is the Orange Book status of Kadian (morphine sulfate ER)?
No Orange Book listings were provided, including:
- applicant holder
- listed drug entry details by strength
- patent numbers and expiration dates
- exclusivity codes (if applicable)
Without this, the Orange Book status cannot be stated accurately.
Which dosage forms and strengths are covered?
Kadian has multiple strengths and is sold in extended-release oral formats. Coverage mapping requires exact product codes and strength-level patent mapping, which are not provided.
How does Kadian compare with competing extended-release morphine products and other ER opioids?
A market model needs competitive set definition (direct ER morphine competitors and broader ER opioid substitutes). No competitive landscape data, market shares, WAC, or payer positioning were provided.
What substitutes typically displace Kadian?
Common substitution vectors depend on:
- payer formulary placement
- opioid safety edits and prior authorization requirements
- patient tolerance and dose equivalence
- marketing and channel incentives within long-acting opioids
No Kadian-specific displacement metrics were provided.
What FDA regulatory status affects Kadian demand (REMS, labeling, safety actions)?
Regulatory status affects uptake through:
- opioid REMS constraints
- labeling updates tied to opioid risk
- safety communications and enforcement posture
No FDA-action timeline or current labeling deltas were provided.
What changes in opioid policy affect sales of Kadian?
A forward projection depends on:
- prescribing policy shifts
- coverage rules for long-acting opioids
- FDA safety communications and state-level limits
No policy and sales-sensitivity inputs are provided.
What market size, revenue, and demand trends apply to Kadian?
No commercial metrics were provided. A credible projection requires:
- recent annual net sales (at least 3-5 years)
- prescription volumes (TRx), new starts, adherence trends
- average selling price and rebate trends
- payer mix changes and contracting outcomes
What data should drive a 5-year projection for Kadian?
A projection normally models:
- base growth from patient population and dose persistence
- elasticity from generic substitution within extended-release opioids
- headwinds from opioid safety scrutiny and payer restrictions
- mitigation from brand retention programs and contracting strategy
No Kadian-specific inputs are provided.
What is a realistic forward revenue projection for Kadian over the next 5 years?
A numeric projection cannot be produced without:
- baseline sales and Rx volume trend
- exclusivity expiration schedule
- expected competitive generic entry timing
- expected impact of litigation or settlements (if any)
No baseline commercial figures and no exclusivity/patent timeline were provided.
Key Takeaways
- A precise clinical-trials update for Kadian requires trial identifiers, sponsor involvement, endpoints, and current enrollment/readout status; none were provided.
- A defensible exclusivity and generic-entry risk view requires Kadian’s current Orange Book patent list with expiration and exclusivity codes; none were provided.
- A credible market analysis and 5-year revenue projection requires a recent baseline of net sales and prescription trends plus an exclusivity-driven competitive calendar; none were provided.
- Without those inputs, no accurate market forecast or timeline can be stated.
FAQs
1) Are there any currently recruiting Kadian (morphine sulfate ER) clinical trials for chronic pain?
Not available from the provided information.
2) Has Kadian been subject to any recent FDA labeling changes related to opioid safety?
Not available from the provided information.
3) What patents in the Orange Book list the Kadian extended-release formulation and when do they expire?
Not available from the provided information.
4) Have any ANDAs for generic Kadian been filed with Paragraph IV challenges?
Not available from the provided information.
5) How quickly does Kadian lose market share after authorized-generic or first-generic launches in ER morphine?
Not available from the provided information.
References
- FDA Orange Book (Drug Products). U.S. Food and Drug Administration.
- ClinicalTrials.gov. U.S. National Library of Medicine.
